(Total Views: 350)
Posted On: 08/18/2021 11:22:55 AM
Post# of 36564
Failure to provide a ‘timely’ update is one thing. But to conflate that with ‘we’re obviously going nowhere’ is very different.
The world is just in round three of the covid fight. Billions have not been vaccinated. The Delta variant is only one of the recent mutations. There will be others. mRNA will never reach this global population. It will only be someone like NGIO...NGIO or someone like that...that will find a way to produce a vaccine that is easy to deliver and which will provide protection from covid in its many mutations. We are far from that objective...years. This is a generational battle, just like climate change. Investors in GNBT and NGIO need to think about this journey not as this quarter or the next but a longer timeline with expectations in alignment with that.
Excellagen and the rest of the stable of Gnbt and NGIO horses are different. I think we can reasonably expect some reportable progress in these other areas. We know that it’s been slow-going, for example, reinvigorating Excellagen, and apparently standing up the medical services platforms, and that other like Altucell are farther out. But it’s not unreasonable to ask for some kind of update. And with respect to these other parts of the GNBT and NGIO family, I fully expect that some of them will eventually be revenue producers.
The world is just in round three of the covid fight. Billions have not been vaccinated. The Delta variant is only one of the recent mutations. There will be others. mRNA will never reach this global population. It will only be someone like NGIO...NGIO or someone like that...that will find a way to produce a vaccine that is easy to deliver and which will provide protection from covid in its many mutations. We are far from that objective...years. This is a generational battle, just like climate change. Investors in GNBT and NGIO need to think about this journey not as this quarter or the next but a longer timeline with expectations in alignment with that.
Excellagen and the rest of the stable of Gnbt and NGIO horses are different. I think we can reasonably expect some reportable progress in these other areas. We know that it’s been slow-going, for example, reinvigorating Excellagen, and apparently standing up the medical services platforms, and that other like Altucell are farther out. But it’s not unreasonable to ask for some kind of update. And with respect to these other parts of the GNBT and NGIO family, I fully expect that some of them will eventually be revenue producers.
(4)
(0)
